Slingshot members are tracking this event:

Lilly to Present Data from Phase 3 Studies on Ixekizumab in Psoriasis and Psoriatic Arthritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Lilly announced that it will present data from its multiple phase 3 trials of Ixekizumab for moderate-to-severe plaque psoriasis and active psoriatic arthritis at the annual meeting of the American Academy of Dermatology.  The data will be presented over the course of 5 days.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 07, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Ixekizumab, Psoriasis, Psoriatic Arthritis